Oral contraceptives (OC) raise plasma triglyceride and VLDL levels, which may be of concern, since some conditions characterized by elevated triglycerides are associated with atherosclerosis. To identify the responsible mechanism, we studied 11 healthy premenopausal women, 5 of whom were taking OC containing 0.035 mg ethinyl estradiol, and 6 of whom were not. Their rates of VLDL and LDL metabolism were measured by endogenously labeling apoB, the protein component of VLDL and LDL, by an intravenous infusion of deuterated leucine. OC use had the greatest effect on the large, triglyceride-rich VLDL subfraction (Sf 60-400), increasing plasma levels threefold and production rates fivefold (P < 0.05). Among OC users, small VLDL (Sf 20-60) levels were 2.2 times higher, and production rates were 3.4-fold higher (P < 0.05). The fractional catabolic rates of large and small VLDL were similar among OC users and nonusers. LDL levels and metabolic rates were not significantly different between the two groups. Thus, contemporary low dose OC substantially raise VLDL levels by increasing the production rate of large, triglyceride-rich VLDL, and not by slowing VLDL catabolism. Since VLDL catabolism is not impaired, we speculate that the hypertriglyceridemia induced by OC may be less atherogenic than that of hypertriglyceridemia resulting from impaired lipolysis. This may explain why long-term OC use does not appear to promote atherosclerosis. (J. Clin. Invest. 1993. 91:2126-2132
Introduction
Women who use oral contraceptives (OC)' have higher levels of plasma triglycerides, the majority of which are carried by VLDL. The estrogen component ofOC is believed to be responsible for this effect, and appears to raise triglyceride levels in a dose-dependent manner ( 1) . This increase in triglycerides may be ofconcern, since some conditions characterized by elevated triglycerides are associated with atherosclerosis (2) . However, the development of atherosclerosis may not be due to the elevated triglycerides per se, but may depend upon the nature of the primary metabolic derangement which caused the high triglyceride levels to occur. For instance, hypertriglyceridemia resulting from increased VLDL synthesis may be less harmful than that resulting from impaired VLDL catabolism. This is supported by the observations that postmenopausal estrogen replacement (3) , moderate alcohol consumption (4) , and cholestyramine, a bile acid sequestering resin (5) , all ofwhich raise triglycerides by increasing VLDL synthesis, have not been found to promote atherosclerosis and in fact appear to lower the risk of coronary heart disease (6) (7) (8) . In contrast, endogenous hypertriglyceridemia, in which VLDL levels rise principally due to impaired catabolism of VLDL (9) , has been associated with cardiovascular disease ( 10 ) . The lipoprotein abnormalities that result from impaired VLDL catabolism may be the factors which are atherogenic, such as the cholesterol ester enrichment of VLDL, or the reduced levels of HDL. Since millions ofwomen currently use OC it is important to delineate the metabolic alterations responsible for the elevation oftriglycerides. Prior work evaluated very high dose OC which are uncommonly used today; one study found OC to both increase triglyceride synthesis as well as impair triglyceride clearance ( 11), whereas another study found OC to increase VLDL apoB production only ( 12) . Furthermore, these studies did not evaluate the effect ofOC on different subpopulations ofVLDL particles, which may be important, since VLDL consists of a heterogenous spectrum of particles with varying triglyceride content and, perhaps, different atherogenicity ( 13, 14) . There has been no work evaluating the effect ofOC on LDL metabolism. We therefore studied the metabolism ofindividual VLDL subfractions and of LDL in nonusers and users of contemporary low dose OC's, to identify the mechanisms by which OC use raises plasma VLDL and triglyceride levels. The rates of VLDL and LDL synthesis and catabolism were measured by endogenous labeling of their primary protein component, apoB, with a nonradioactive amino acid tracer, trideuterated leucine (D3-leucine).
Methods
Subjects. 11 healthy premenopausal women, ages 22-27, were enrolled into this study. Nine were dieticians, and two were research associates. The first six subjects (three OC users, and three nonusers) had been randomly selected to participate in a pilot study oflipoprotein metabolism. After marked differences in VLDL metabolism were noted between the OC users and nonusers, an additional five subjects (two OC users and three nonusers) were recruited to complete the final study group. The five OC users had all taken oral contraceptives containing 0.035 mg ethinyl estradiol for more than I y. Four ofthe five OC users took oral contraceptives containing norethindrone, given as 1 mg daily for 21 d (Ortho-Novum 1/35; Ortho Pharmaceutical Corp., Raritan, NJ) for subjects 1 and 4; or given as 0.5 mg, 0.75 mg, and 1.0 mg given sequentially for 7 d each (Ortho-Novum 777; Ortho Pharmaceutical) for subjects 2 and 3. The fifth OC user took an OC containing ethynodiol diacetate, given as 1 mg daily for 21 d (Demulen; Searle Pharmaceuticals Inc., Skokie, IL) for subject 5. The other six subjects (6) (7) (8) (9) (10) (11) were not taking OC and had regular menstrual cycles. No subjects used any other prescription drugs or tobacco, nor consumed more than 15 g of ethanol daily. The composition oftheir usual diet was analyzed by a semiquantitative food frequency questionnaire (15) . Subjects recorded the duration ofexercise performed over one month's time. Subjects gave informed consent, and the study was approved by the Committee for the Protection of Human Subjects at Brigham and Women's Hospital. All 11 subjects completed the entire study.
Protocol. (Fig. 1) . D3-leucine is incorporated by the liver into apoB, which is assembled into VLDL and secreted into the circulation; as VLDL is converted into LDL, the label appears in LDL apoB (Fig. 1 ). Blood specimens were obtained through a second intravenous catheter in the contralateral arm every 15 minutes for the first 2 h, and hourly thereafter. For the first 4 h, subjects were restricted to noncaloric and noncaffeinated fluids. This was followed by a standardized fat-free and leucine-free diet containing 60% of the total daily calories required for maintenance, served as lunch (at 4 h), dinner (at 10 h), and evening snack (at 13 h). The diet was leucine free to prevent "dilution" of plasma leucine enrichment by the intake of unlabeled (dietary) leucine. The isotopic enrichment curves of VLDL subfractions and unfractionated VLDL during the fasting period were used to determine their metabolic rates. In this way, the measurement of VLDL metabolism would not be altered by any acute effect of feeding on VLDL production or clearance. Plateau enrichments were unaffected by meals since steady-state enrichment had already been achieved. Specimen analysis. Blood was collected into tubes containing disodium EDTA, 1.5 mg/ml; aprotinin, 0.01 mg/ml; PMSF, 17.5 ,g/ml; and gentamicin, 0.05 mg/ml. Blood specimens were then centrifuged to separate plasma. VLDL (density < 1.006 g/ml) was immediately prepared from plasma overlayered with 2 ml NaCl 0.9%, and spun in a type 70.1 Ti rotor at 70,000 rpm in an L8-70M instrument (Beckman Instruments, Palo Alto, CA) for 2.5 h. During one of each subject's admissions, VLDL subfractions were prepared from a second aliquot ofplasma: large (Svedberg units offlotation [Sf] 60-400) and small (Sf 20-60) VLDL were isolated by cumulative-rate, density-gradient ultracentrifugation ( 16) using a type 41 SW rotor (Beckman Instruments).
LDL (density, 1.019-1.063 g/ml) was isolated by sequential preparative ultracentrifugation at 25,000 rpm for 26 h, in a type 25 rotor (Beckman Instruments) adjusting plasma density with potassium bromide (17) . High density lipoprotein was separated from plasma by precipitation after the addition of dextran and magnesium chloride ( 1 8 ). Cholesterol and triglyceride concentrations were determined by enzymatic methods (19) (Boehringer-Mannheim, Indianapolis, IN). ApoB concentrations were measured by a direct ELISA using a polyclonal antibody (obtained from Dr. Peter Herbert, Brown University, Providence, RI) and an alkaline phosphatase conjugate of the same antibody. VLDL-apoB subfraction concentrations, measured by ELISA, were validated by determining the apoB concentrations by gas chromatography/mass spectroscopy (GC/MS) which uses the peak area of leucine from hydrolyzed apoB. Linear regression analysis of ELISA measurements on gas chromatography/mass spectroscopy measurements demonstrates a slope of 0.94 for apoB in large VLDL and 1.04 for apoB in small VLDL. The intraassay coefficients of variation for "blinded" control samples was 1.2% for cholesterol, 2.7% for HDL cholesterol, and 6.4% for apoB.
ApoB was precipitated from fractionated lipoproteins by isopropanol and washed three times (20) . We and others (20, 21 ) determined by polyacrylamide gradient gel electrophoresis that the isopropanol precipitate after appropriate washing is free of apoproteins other than apoB. ApoB was hydrolyzed into component amino acids by heating at 120°C with 6 N hydrochloric acid for 16 h. Free amino acids were isolated from plasma by chromatography on AGSOW-X8 resin (BioRad Laboratories, Richmond, CA). All amino acids were converted to heptofluorobutyric acid derivatives. The proportion of D3-leucine in each specimen was measured using a 5890 gas chromatograph with a 5988A mass spectrometer (Hewlett Packard, Palo Alto, CA). of LDL was calculated according to the theoretical principle that FCR is equal to the initial rate of appearance of label in a product (LDL apoB) divided by the precursor enrichment (VLDL apoB) if the precursor enrichment is constant (22) . This approach was valid for LDL since the enrichment in VLDL-apoB was constant after 5 h (Fig. 1) . This approach could not be used to analyze VLDL subfractions since the initial appearance of label in small VLDL occurs before the enrichment in large VLDL reaches steady state (Fig. 2) . We therefore calculated the metabolic parameters of VLDL subfractions by computer modeling using the National Institutes of Health SAAM-30 (simulation, analysis, and modeling) software program. This program uses the rates of appearance of deuterated leucine in apoB of large VLDL and small VLDL, and their plasma pool sizes to calculate metabolic rates. We used a model (Fig. 3) dieticians, these subjects consumed a diet low in total fat, saturated fat, and sucrose; and high in fiber and complex carbohydrates. Lipoprotein levels. The mean plasma concentrations of all measured VLDL components (measured during all metabolic studies for each subject) were significantly greater in OC users (Table II) : VLDL cholesterol, 1.6 times higher (P < 0.05); VLDL triglyceride, 1.7 times higher (P < 0.05); and VLDL apoB, 2.4 times higher (P < 0.05). Of note is that VLDL in OC users is not enriched in cholesterol or triglyceride; the molar ratio of VLDL cholesterol to VLDL apoB is 4,200 in OC users and is 6,400 in nonusers; the molar ratio of VLDL triglyceride to VLDL apoB is 6,900 in OC users and is 9,800 in nonusers. In addition, each subject had VLDL apoB subfractions measured during one metabolic study, and the higher level of VLDL apoB in OC users was found to be distributed between both VLDL subfractions: large VLDL apoB (Sf 60-400) was 3.0 times higher (P < 0.05) and small VLDL apoB (Sf 20-60) was 2.2 times higher (P < 0.05) compared to OC nonusers (Table  III) . The mean plasma concentrations of total cholesterol, HDL cholesterol, LDL cholesterol, and LDL apoB were not significantly different between the two groups.
Calculation ofmetabolic rates. The fractional catabolic rate (FCR)
Reproducibility of metabolic measurements. LDL fractional catabolic rates were highly reproducible when measured twice, 1 mo apart in six subjects: the intraindividual coefficient of variation was only 3.4%. Thus both methodologic and biologic variability is quite low. Methodologic variability may have been minimized by the multiple measurements obtained: LDL FCR is calculated using both (a) the slope of the initial linear appearance of label in LDL, determined from measurements obtained during at least 10 different times; and (b) the precursor (i.e., VLDL) enrichment at plateau, determined by averaging typically [8] [9] [10] The values for LDL and VLDL metabolic rates ofOC nonusers, measured by endogenous stable isotope labeling, are comparable to those obtained in studies by reinfusion of lipoproteins exogenously labeled using radioiodination (Table  IV) . LDL measurements are similar to those obtained in a study of five postmenopausal women (23); large VLDL measurements are similar to those obtained in a study of seven healthy subjects, ages 22-48 (9). To our knowledge, there is no single metabolic study of VLDL subfractions and LDL in normolipidemic young women that used radioidinated lipoproteins that would be directly comparable to the present study.
Metabolic measurements. OC users had significantly greater rates of VLDL apoB production compared to nonusers (Fig. 4) : for large VLDL (Sf60-400) it was 4.9 times higher (P < 0.01 ); and for small VLDL (Sf20-60) it was 3.4 times higher (P < 0.05). The mean production rates of unfractionated VLDL isolated by fixed angle ultracentrifugation were also significantly higher among OC users: 21 nmol/kg per d, vs. 11 nmol/kg per d for nonusers (P < 0.05). There was no overlap between groups for large VLDL production rates. Exclusion of the subject who took the OC which contained ethynodiol diacetate did not alter our results.
In contrast, the two groups did not have significantly different FCR for large VLDL, small VLDL, and LDL (Fig. 4) . Although the mean production rate of LDL was 15% higher in OC users, this difference was not statistically significant (P -0.77).
Discussion
We found that women who use contemporary low dose oral contraceptives, which contain 0.035 mg ethinyl estradiol, have significantly higher plasma levels of VLDL triglyceride, apoB, and cholesterol. We further found that these greater VLDL levels are due to increased VLDL production, and are not the result of reduced VLDL clearance. In particular, OC use has the greatest effect on large, triglyceride-rich VLDL, increasing its plasma concentration threefold, and production rate fivefold. The increases in small VLDL concentrations and production rates were statistically significant but smaller in magnitude The present study did not find OC's to increase VLDL catabolic rates. Such an increase might be expected, based on the work of Kissebah et al. ( 11) who studied women using OC containing 0.050 mg ethinyl estradiol with varying progestins. They found that VLDL triglyceride levels were twofold higher in OC users due to both twofold higher production rates and 45% higher catabolic rates. They attributed the latter effect to the progestin component of the OC, since their comparison group of estrogen-only users did not show increased rates of VLDL catabolism. That the present study did not find an increase in VLDL catabolic rates may be due to the lower dose of progestins currently used. Alternatively, a modest effect of the progestin component on FCR (in contrast to the several-fold effect of estrogen on VLDL production) might not have been detected, since this study had sufficient statistical power (80%) to detect changes in VLDL FCR of only 50% or more.
OC users and nonusers had similar rates of LDL production and catabolism, in contrast to the marked differences in their rates of VLDL metabolism. This study had adequate statistical power (80%) to detect a change in LDL FCR of 27% or greater. However, increases in LDL FCR of this magnitude might be expected, since 2 mg micronized estradiol (which is far less potent than ethinyl estradiol) given to postmenopausal women increased the FCR of LDL by 38%, from 0.24 to 0. Users vs. nonusers, $P < 0.01 and **P < 0.005.
